Beranda › Karsinoma Duktal In Situ (DCIS) › Florida
Uji klinis Karsinoma Duktal In Situ (DCIS) di Florida
7 studi untuk Karsinoma Duktal In Situ (DCIS) mencari peserta di lokasi di Florida.
Kota di Florida
Teks studi resmi (Bahasa Inggris)
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Moffitt Cancer Center, Tampa
Menerima pesertaFase 2
Usia 18 ke atas · Wanita · Diperbarui 28 Sep 2026 · NCT06075953Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
- TopLine MD Alliance, Miami
Menerima pesertaSukarelawan sehat diterima
Usia 30 hingga 74 · Wanita · Diperbarui 21 Sep 2026 · NCT02620852Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- Baptist Alliance Miami Cancer Institute, Miami
Menerima pesertaFase 2
Usia 45 ke atas · Wanita · Diperbarui 21 Sep 2026 · NCT04084730Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions
- University of Florida, Gainesville
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06903468The PREDICT Registry:
- Baptist MD Anderson Cancer Center, Jacksonville
- BayCare Health System, Tampa
- University of South Florida, Tampa
Menerima pesertaStudi observasional
Usia 30 hingga 85 · Wanita · Diperbarui 17 Apr 2026 · NCT03448926A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- Mayo Clinic in Florida, Jacksonville
Menerima pesertaFase 1
Usia 18 ke atas · Wanita · Diperbarui 5 Mar 2026 · NCT04144023Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
- CyberKnife Center of South Florida in Stuart, Stuart
- CyberKnife Centers of Tampa Bay, Tampa
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 50 hingga 100 · Wanita · Diperbarui 5 Agu 2022 · NCT04985032Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.